In an breakthrough scientific discovery, scientists have found that a common diabetes medication taken by millions globally—metformin, may provide unexpected protection against acute myeloid leukemia (AML), a fast-growing and frequently fatal type of blood cancer. This has been established by a new study by the University of Cambridge, which has been published in the highly-respected journal Nature. The study suggests metformin to be a low-cost, safe preventative therapy for individuals who are at high risk of developing AML.This finding may represent a paradigm change in the approach to cancer prevention in medicine—particularly in hematological malignancies where early intervention is usually restrictive.In contrast to solid cancers like breast or prostate cancer, which at times may be removed surgically, blood cancers are more difficult to localize and destroy. As Cambridge Stem Cell Institute Professor George Vassiliou describes it, "With blood cancers, we must first find people at risk and then apply medical treatments to halt cancer growth across the body." AML, which begins in the bone marrow and develops quickly, is an example of this difficulty.Approximately 3,100 individuals in the UK are diagnosed with AML every year. It has a poor prognosis and few treatment options, especially in the elderly. Although the latest advances in blood testing are able to indicate individuals at risk years earlier than before, to date, there has not been a sure way to stop AML from forming.How Diabetes Drug Interrupts Cancer Development at the Cellular Level?Scientists targeted their research on DNMT3A, a gene commonly mutated in AML patients. This one mutation is thought to trigger as much as 15% of all AML. Metformin seems to break the energy metabolism of these pre-leukemic cells, targeting their aberrant growth pathways. By disabling the cells' capacity to produce energy, metformin stops them from developing into full-blown leukemia.Additional analysis of health information from more than 412,000 UK Biobank participants reinforced the link. Metformin users had a significantly lower incidence of damaging mutations in the DNMT3A gene, whether or not they had diabetes. The results indicate a protective effect that is independent of the drug's initial purpose.What is Metformi?The origins of metformin trace back to medicinal plants used during medieval Europe. Isolated from Galega officinalis, a plant used in traditional medicine to cure urinary and metabolic problems, its active ingredient—guanidine—was discovered to lower blood sugar in the early 20th century. Although it was disfavored for a period, metformin was re-released and approved in Europe in the 1950s and subsequently by the FDA in 1995. It's now most commonly prescribed diabetes medication globally, especially in patients who have type 2 diabetes and are unable to regulate blood sugar levels by diet and exercise alone.How Metformin Works?Decreasing the level of glucose absorbed by the intestines through food.Suppressing the liver's release of glucose.Increasing insulin sensitivity, so that the body can utilize glucose more effectively.These metabolic actions are not only helpful for controlling diabetes, but potentially for stopping or slowing other disease processes—such as cancer.Benefits of MetforminWhat's even more amazing is how metformin's benefits go beyond controlling blood sugar. According to Harvard Health and other medical centers, the medication has been linked with:Reduced cardiovascular mortality among diabeticsModerate weight lossDecreased risk for type 2 diabetes in persons with prediabetesHelp with polycystic ovary syndrome (PCOS)Lower risk for cancers such as breast, colon, and prostatePossible diminishment of risk for dementia and strokeOff-label prescriptions have also been used for some of these indications in metformin, highlighting the drug's versatile utility and solid safety profile.One of the main advantages of metformin is its long history of safety. Taken by millions of people over many decades, it tends to have only minor side effects—e.g., nausea, bloating, or altered taste. Serious side effects, such as lactic acidosis, are infrequent and typically only occur in those with existing kidney disease.As Blood Cancer UK's Director of Research Dr. Rubina Ahmed put it, "Repurposing existing, safe drugs such as metformin allows the possibility that new treatments might get to people earlier, without going through the extensive drug development pathways."